Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (January 2016)
28 slides from Recce Pharmaceuticals's investor presentation, Jan 18, 2016
Slide 1: ASX Announcement: Broker Presentation
ASX ANNOUNCEMENT 18 January 2016 Broker Presentation Announcements Office Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000 Attached are the presentation slides for a presentation that will be given by Recce’s executive team shortly. For further information please visit www.recce.com.a
Slide 2: Investor Presentation
Investor Presentation Our Mission: “To target the global health problem of superbugs” “One of the greatest threats of human health today” World Health Organisation 1
Slide 3: Disclaimer
Disclaimer ALL CURRENCY AMOUNTS ARE IN AUD UNLESS STATED OTHERWISE. DISCLAIMER This presentation has been prepared by Recce Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You
Slide 4: Key Risk Factors
Key Risk Factors • Regulatory tests still to be done may reveal weaknesses in the efficacy/safety profile of RECCE® antibiotics • Competitive antibiotics may arise, and redesign of Recce’s objectives may result • Access to the employment or services of specialists may be at times limiting • Patents
Slide 5: Business Overview
Business Overview Why are RECCE® antibiotics important? • Continued use of commercial antibiotics has Technical Developments ($K) led to antibiotic-resistant bacteria superbugs Year 1 Year 2 - major world health issue • RECCE® antibiotics are unlike anything Pilot Manufacture 255 310 developed befor
Slide 6: Technology Overview – E. coli (superbug)
Technology Overview – E. coli (superbug) Pre-infection Full infection After 1 hour treatment with RECCE® synthetic antibiotic Complete kill 5
Slide 7: Technology Overview – P. aeruginosa (superbug)
Technology Overview – P. aeruginosa (superbug) Pre-infection Full infection After 1 hour treatment with RECCE® synthetic antibiotic Complete kill 6
Slide 8: RECCE antibiotics kill at practical speeds
RECCE® antibiotics kill at practical speeds Rates of kill of standard bacteria S. aureus E. coli P. aeruginosa S. pyogenes C. difficile 20 – 60 20 – 60 1 – 24 20 – 60 20 – 60 minutes minutes hours minutes minutes Rates of kill of Superbugs S. aureus E. coli P. aeruginosa The same kill-rates for stan
Slide 9: RECCE antibiotics do not Fail
RECCE® antibiotics do not Fail Number of repetitive uses before displaying loss of antibiotic activity S. aureus E. coli P. aeruginosa Commercial Commercial Commercial antibiotic antibiotic antibiotic 8 4 10 RECCE® Antibiotic >25 After repetitive use, the commercial antibiotic loses activity; RECCE®
Slide 10: Technology – How it works
Technology – How it works Recce’s Response to the Global Health Problem An entirely new/novel human new antibiotic has not come onto the market since 1962. RECCE® antibiotics attack protein in the cell wall of ALL bacteria – outward pressure causes only them to rupture. Only Bacteria have internal p
Slide 11: Manufacture
Manufacture 10
Slide 12: Natural vs Synthetic – Recce's theory
Natural vs Synthetic – Recce’s theory • Commercial antibiotics are mainly naturally derived; RECCE® antibiotics are synthetic • Recce’s theory is that NATURE WILL HAVE ALREADY FORMED SUPERBUGS TO THESE NATURAL ANTIBIOTICS • Differently, NATURE WILL NOT HAVE FORMED SUPERBUGS TO SYNTHETIC ANTIBIOTICS
Slide 13: Improved Manufacture
Improved Manufacture 1. Higher Quality 2. Lower raw-material and labor, on-going expenses 12
Slide 14: Improved Manufacture
Improved Manufacture 3. Simple plant design 4. Manufacturing plant smaller 13
Slide 15: The Board
The Board 14
Slide 16: Board of Directors
Board of Directors The board-structure is appropriate to the current needs of Recce – and will change as the needs change. DEVELOPMENT RESEARCH & MARKETING MANUFACTURE 15
Slide 17: Board of Directors
Board of Directors Dr Graham Melrose, BSc(Hons), PhD, MBA, FRACI, CChem, FAICD • Founder of Recce and inventor of RECCE® antibiotics • Previously, founded Chemeq Ltd and under his leadership and R&D direction, achieved over a three-year period, the top capital gain of all companies listed on the ASX
Slide 18: Board of Directors
Board of Directors James Graham B.Com.(Entrepreneurship), GAICD – Responsible for Marketing • Committee-member of W.A. Angel Investors; entrepreneurship and marketing • General Manager of start-up marine company with sales in Australia, Asia and Europe • Investor (Non-professional) in ASX-listed tec
Slide 19: Board of Directors
Board of Directors Professor Dongke Zhang FTSE, PhD, FIChem Eng, CEng, CSci, FIEng Aust, CPEng, FAIE • Designed and built the first pilot plant for Chemeq • Technical Executive/Director of innovative technology companies • Consultant to a range of Australia’s top companies • Awarded the status of Di
Slide 20: Development
Development 19
Slide 21: Projected Development
Projected Development Estimates by Recce, based upon FDA protocols 20
Slide 22: Intellectual Property
Intellectual Property* Patent Attorneys: Phillips Ormonde Fitzpatrick - Melbourne Patent Filed Status Expiry Family 1 Australia Granted 2028 USA Granted 2029 Europe Granted 2028 Japan Granted 2028 China Granted 2028 Patent Family 2 All PCT Countries Pending 2034 *Manufacturing & marketing monopoly o
Slide 23: RECCE antibiotics – Human Markets ($40B)
RECCE® antibiotics – Human Markets ($40B) Sepsis • “Sepsis affects over 26 million people worldwide each year - one third die”* • “It is the largest killer of children and new-born infants in the world” • “Sepsis is increasing at an annual rate of 8-13%” • “In the United States, sepsis kills more pe
Slide 24: RECCE antibiotics - Human Markets
RECCE® antibiotics - Human Markets Helicobacter pylori • “H. Pylori is estimated to effect half of the worlds population” • “It is very strongly associated with human gastritis, peptic ulcers and gastric cancer”. Helicobacter pylori in the 21st Century, v17, pg 1 23
Slide 25: RECCE antibiotics - Human Markets
RECCE® antibiotics - Human Markets E.coli “1.7 billion cases… of diarrhoeal disease every year… responsible for killing around 760,000 children under 5 years every year.” World Health Organisation, Diarrhoeal Disease, Fact Sheet 330, April 2013 24
Slide 26: RECCE antibiotics
RECCE® antibiotics Three groups of 10 mice were each infected with S.aureus (superbug) • All ten mice treated with RECCE® antibiotic were saved • Nine mice treated with current antibiotic (Oxacillin) survived • Four mice that had no treatment at all, survived. In mice, Efficacy/Safety was achieved i
Slide 27: RECCE antibiotics – a Technology
RECCE® antibiotics – a Technology Investment in Recce Ltd is highly speculative. However, compared to the risk of a single opportunity from a one-use product; Recce’s technology enjoys the added security of multiple product opportunities. 26
Slide 28: Corporate Directory
Corporate Directory Lead Manager & Sponsoring Broker Solicitors Patent Attorneys Investigating Accountants Investor Relations/Media 27